Key facts
- NeOnc Technologies Holdings (NAS: NTHI)’s last known valuation is $282.0M (Jun 2024).
- It has raised $88.9M; the latest was PIPE ($16.0M) in Jan 2026.
- Status: Publicly Held.
- ·Watchlist + deal alerts for NeOnc Technologies Holdings (NAS: NTHI)
- ·The full record, as it builds
Funding rounds
No funding rounds for NeOnc Technologies Holdings (NAS: NTHI) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeOnc Technologies Holdings (NAS: NTHI)
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
- Sector
- Healthcare
- HQ
- Calabasas, CA, United States
- Founded
- 2008
- Employees
- 5
- Website
- neonc.com/
- Ownership
- Publicly Held
NeOnc Technologies Holdings (NAS: NTHI) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeOnc Technologies Holdings (NAS: NTHI) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeOnc Technologies Holdings (NAS: NTHI) in its N-PORT filings yet. We sweep new filings monthly.